BioSpace

Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.

作者 BioSpace

1 分钟阅读
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察